Shintaro Yamaguchi, Junichiro Irie, Masanori Mitsuishi, Yuichi Uchino, Hideaki Nakaya, Ryo Takemura, Emi Inagaki, Shotaro Kosugi, Hideyuki Okano, Masato Yasui, Kazuo Tsubota, Kaori Hayashi, Jun Yoshino, Hiroshi Itoh
Obesity and aging are major risk factors for several life-threatening diseases. Accumulating evidence from both rodents and humans suggests that the levels of nicotinamide adenine dinucleotide (NAD+ ), a regulator of many biological processes, declines in multiple organs and tissues with aging and obesity. Administration of an NAD+ intermediate, nicotinamide mononucleotide (NMN), replenishes intracellular NAD+ levels and mitigates aging- and obesity-associated derangements in animal models. In this human clinical study, we aimed to investigate the safety and effects of 8-week oral administration of NMN on biochemical, metabolic, ophthalmologic, and sleep quality parameters as well as on chronological alterations in NAD+ content in peripheral tissues...
February 28, 2024: Endocrine Journal